Incretin Atlas › Trials › REBUILDING-1 (RAY1225, NCT06254261)
REBUILDING-1 (RAY1225, NCT06254261)
RAY1225 · obesity
Design
- Molecule(s)
- RAY1225
- Population
- obesity
- Phase
- 2
- Participants
- 172
- Duration
- 24 weeks
- Registry
- NCT06254261
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 mg Q2W | obesity china | 24 | 172 | — | —−10.1 % vs −3.5 % estimand not specified | — | — | — | — | — | — | — | press release |
| 6 mg Q2W | obesity china | 24 | 172 | — | —−13.0 % vs −3.5 % estimand not specified | — | — | — | — | — | — | — | press release |
| 9 mg Q2W | obesity china | 24 | 172 | — | —−15.1 % vs −3.5 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (3)
- 3 mg Q2W · weight_unsp · HKEX filing
治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
- 6 mg Q2W · weight_unsp · HKEX filing
治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
- 9 mg Q2W · weight_unsp · HKEX filing
治疗 24 周体重呈剂量依赖性下降,体重较基线相对变化的最小二乘均数分别为-10.05%、-12.98%和-15.05%,安慰剂组为-3.55%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: REBUILDING-1 (RAY1225, NCT06254261). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/rebuilding-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.